Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Daily Stock Opinions and Ratings
Stockchase Opinions

The Monthly Gems by Allan TongViemed HealthcareVMD.TOTOP PICKAug 01, 2023

When markets hit 52-week highs and signs point to frothiness, where do you put your money? The safe route is a savings account paying 5%. The riskier one, but could pay you more later, lies in unloved sectors. Healthcare is one. As a ventilator company, Viemed thrived during the pandemic, which explains its 174% rise in the last five years. This year has been a different story as VMD jumped to $16.25 last April, but has sunk to $11.50. (These are its TSX prices. This Louisiana-based company trades on the NYSE as well.)

The Monthly Gems by Allan TongThe Monthly Gems by Allan Tong
Unknown
Unlock Rating
$11.70

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

PAST TOP PICK

Viemed Healthcare(VMD.TO)

Jan 02, 2024
(A Top Pick Jun 01/22, Up 51%)

Their numbers continues to soar, but shares fell last year over concerns that the hit diet drugs will impact them. But business continues to bs strong as they grow revenues and earnings. Trades at a reasonable PE.

Photo of Bruce Campbell (2)Bruce Campbell (2)Unlock Rating
$10.45

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
PAST TOP PICK

Viemed Healthcare(VMD.TO)

Jul 28, 2023

(A Top Pick Jun 01/22, Up 73%)

Excellent performance in stock reflective of demand for healthcare tech.
Continues to hold.
Happy with results.

Photo of Bruce Campbell (2)Bruce Campbell (2)
Owned
Unlock Rating
$11.90

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
BUY

Viemed Healthcare(VMD.TO)

May 15, 2023
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

VMD EPS of 4c beat estimates of 3.5c; Revenue of $39.6M beat estimates of $38.5M. EBITDA of $8.3M beat estimates by 3%. Sales rose 23%; EPS though was flat year over year. EBITDA rose 15%. 2Q  Guidance was maintained and another acquisition was announced. Cash rose to $23.5M (no debt). We would consider it a good quarter. 
Unlock Premium - Try 5i Free

Photo of Stockchase InsightsStockchase InsightsUnlock Rating
$14.57

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
BUY

Viemed Healthcare(VMD.TO)

Sep 27, 2022
Their ventilator business has grown in recent years tough they struggled to access Covid patients in hospitals. They had great revenues in their last quarter. They're expanding operations as they enter new markets. EBITDA was lower than expected, so shares pulled back. They trade at half the PE of their peers. The CEO is one of the biggest shareholders. (Analysts’ price target is $15.86)
Photo of Bruce Campbell (2)Bruce Campbell (2)
Owned
Unlock Rating
$7.65

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
TOP PICK

Viemed Healthcare(VMD.TO)

Jun 01, 2022
In-home, non-invasive respiratory devices. Grows organically and by acquisition. Earnings beat for second consecutive quarter. Awesome management. Growing phenomenally, projected 25% topline growth over next year. Profitable, big cash balance, buying back stock. Discount to peers. NASDAQ listing should generate interest. (Analysts’ price target is $15.01)
Photo of Bruce Campbell (2)Bruce Campbell (2)Unlock Rating
$6.94

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
PAST TOP PICK

Viemed Healthcare(VMD.TO)

Mar 25, 2021
(A Top Pick Apr 27/20, Up 16%) Covid has indirectly increased their business. Growing organically and via acquisitions. Reasonable multiple. Either multiple expansion or a takeover target.
Photo of Bruce Campbell (2)Bruce Campbell (2)
Owned
Unlock Rating
$11.74

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
BUY

Viemed Healthcare(VMD.TO)

Feb 22, 2021
There is a lot of growth in this name. They had a bit of a windfall selling equipment during COVID. There is a lot of positive news coming out about their in-home care. There are a lot of positive drivers in this business.
Photo of Jennifer RadmanJennifer Radman
Owned
Unlock Rating
$13.10

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
TOP PICK

Viemed Healthcare(VMD.TO)

Feb 02, 2021
Enjoys strong tailwinds from aging demographics though Covid made it difficult to access older patients. They continue to be acquisitive. Good valuation. They release earnings shortly and this could move the stock higher. He recently bought this. (Analysts’ price target is $16.02)
Photo of Bruce Campbell (2)Bruce Campbell (2)
Owned
Unlock Rating
$12.15

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
DON'T BUY

Viemed Healthcare(VMD.TO)

Nov 17, 2020

He didn't like it for a while, but now more than before. The telehealth space is getting crowded and they've had issues with CMS code. It's a good American company, though doesn't receive much attention here. VMS is merely okay. He prefers other names like Knight Therapeutics. It's a decent, second-tier company.

Photo of Peter HodsonPeter HodsonUnlock Rating
$11.32

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
HOLD

Viemed Healthcare(VMD.TO)

Oct 06, 2020
He got stopped out of it a while ago. VMD relies on Medicare for a lot of revenues. Clients use sleep-aid systems that are put through Medicare. This revenue stream is coming up for review by Medicare , so this is a risk. Otherwise, VMD checks a lot of boxes. Hold.
Photo of Jason Del VicarioJason Del VicarioUnlock Rating
$11.59

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
BUY

Viemed Healthcare(VMD.TO)

Jun 30, 2020
They provide home equipment and therapy to deal with sleep apnea and other respiratory issues. Earnings are expected to grow 75%. 2021 ROE 37% as earnings rocket up, expected to jump 85% in 2020 and 16% in 2021. PE is 18x 2020, and 22x in 2021. Positive free cash flow which should double. It could join a U.S. index which will boost the stock. $15.25 price target or 9% upside.
Photo of Robert McWhirterRobert McWhirterUnlock Rating
$13.94

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
TOP PICK

Viemed Healthcare(VMD.TO)

Apr 27, 2020
They provide non-invasive ventilators. Medicare is no longer going through a competitive bidding process. (Analysts’ price target is $13.07)
Photo of Bruce Campbell (2)Bruce Campbell (2)
Owned
Unlock Rating
$9.44

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
COMMENT

Viemed Healthcare(VMD.TO)

Oct 07, 2019
It broke above $3.20 and so far it looks okay, but this trades at low volumes.
Photo of Keith RichardsKeith RichardsUnlock Rating
$9.69

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
PAST TOP PICK

Viemed Healthcare(VMD.TO)

Sep 23, 2019
(A Top Pick Sep 24/18, Up 44%) He got stopped out, a mistake. Very profitable, no debt. But they had concentration risk--they need to diversify their customer base. He might buy them back.
Photo of Jason Del VicarioJason Del Vicario
No
Unlock Rating
$9.28

Stock price when the opinion was issued

$10.45

As of Dec 21, 2023. Market Open.

0
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica